DPP-IV inhibitors are used in the treatment of T2DM based on their ability to extend postprandial levels of circulating plasma GLP-1 and GIP, thereby improving insulin secretion and helping to maintain good blood glucose control. This evidence concerns the gene INS and type 2 diabetes mellitus.